Compare XBP & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBP | MDXH |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Belgium |
| Employees | 10200 | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 21.1M |
| IPO Year | N/A | 2021 |
| Metric | XBP | MDXH |
|---|---|---|
| Price | $3.63 | $0.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $7.67 |
| AVG Volume (30 Days) | 25.6K | ★ 524.3K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.59 | $30.78 |
| Revenue Next Year | $5.75 | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.40 |
| 52 Week High | $8.55 | $5.33 |
| Indicator | XBP | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 32.78 |
| Support Level | $3.31 | N/A |
| Resistance Level | $4.80 | $3.79 |
| Average True Range (ATR) | 0.36 | 0.03 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 89.21 | 7.80 |
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.